Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture
The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate
| Condition(s) | Patients With an Abdominal Aortic Aneurysm of 39-49 mm in Diameter |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate is commonly used as a nutritional supplement specially by athletes to increase muscle strength. They can be mixed with formula or other foods. Subjects will be followed for up to 5 years. |
| Who can participate | Inclusion Criteria: 1. Presence of an infrarenal AAA with a maximum diameter of 39-49 mm; 2. Han nationality; 3. Between 50 years or more, no gender limit; 4. No mental illness; 5. No history of supplement allergy or supplement allergy; 6. Subjects voluntarily participate in this study, sign an informed consent form, have good compliance, and cooperate with follow-up. Exclusion Criteria: 1. Previous infrarenal aortic surgery; 2. Planned major surgery; 3. Known aortic dissection; 4. Have received any other clinical trial treatment within 1 year; 5. Systemic treatment with corticosteroids or other systemic immunomodulatory therapy; 6. Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; 7. Known or suspected inherited conne |
| Ages | 50 Years |
| Sex | All |
| Lead sponsor | RenJi Hospital |
| Locations | Shanghai, China |
| Start date | 2021-02-01 |
| NCT ID | NCT04723888 |
| Official listing | https://clinicaltrials.gov/study/NCT04723888 |